Lifeward Ltd. (LFWD)
Market Cap | 14.97M |
Revenue (ttm) | 25.00M |
Net Income (ttm) | -19.30M |
Shares Out | 8.81M |
EPS (ttm) | -2.23 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 357,136 |
Open | 1.480 |
Previous Close | 1.490 |
Day's Range | 1.473 - 1.780 |
52-Week Range | 1.410 - 9.100 |
Beta | 2.07 |
Analysts | Strong Buy |
Price Target | 13.00 (+664.71%) |
Earnings Date | Feb 25, 2025 |
About LFWD
Lifeward Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological r... [Read more]
Financial Performance
In 2023, Lifeward's revenue was $13.85 million, an increase of 151.39% compared to the previous year's $5.51 million. Losses were -$22.13 million, 13.1% more than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for LFWD stock is "Strong Buy" and the 12-month stock price forecast is $13.0.
News
Coverage for ReWalk Personal Exoskeleton Expands as Hungary Joins the U.S. and Germany with a Policy Providing Access to Exoskeletons
Research at the prestigious Semmelweis University, Budapest, Hungary has led the way in achieving government coverage in Hungary with a code for exoskeleton training that expands access to additional ...
Lifeward Ltd. (LFWD) Q3 2024 Earnings Call Transcript
Lifeward Ltd. (NASDAQ:LFWD) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Mike Lawless – Chief Financial Officer Larry Jasinski – Chief Executive Officer Conferen...
Lifeward Ltd. Reports Third Quarter 2024 Financial Results
Second consecutive quarter of 20 ReWalk systems sold Robust growth in U.S. ReWalk pipeline of approximately 70 qualified leads for potential claim submission with Medicare and other U.S. payors MARLBO...
Lifeward to Report Third Quarter Financial Results on November 12, 2024
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to...
Lifeward Ltd. to Present at ThinkEquity Conference on Oct 30, 2024
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to...
Lifeward Launches Direct Sales of AlterG Product Line in Germany
Direct sales of AlterG products through the Lifeward GmbH sales team expected to improve margins and increase AlterG revenues in Germany, accelerating Lifeward's path to profitability Direct sales of ...
ReWalk Robotics Ltd. Finalizes Corporate Name Change to Lifeward Ltd.
Following approval by the shareholders and the Israel Companies Registrar, Lifeward has completed is rebranding initiative with a formal name change of the parent company in Israel Following approval ...
Lifeward Announces Appointment of Dr. Keith E. Tansey as Consulting Director of Clinical Research
A past-president of the American Spinal Injury Association, Dr. Tansey brings Lifeward over 30 years of experience in research and treatment of spinal cord injuries as a practicing Physician, Professo...
Lifeward's First Annual Step Challenge Donates €5,000 to German Association for People Living with Spinal Cord Injury
As part of the fundraising “Step Challenge”, ReWalk users in Germany completed 424,844 steps to raise 5,000 Euros for the European Spinal Cord Injury Federation (“ESCIF”) As part of the fundraising “S...
Lifeward to Present at the H.C. Wainwright 26th Annual Global Investment Conference
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Sept. 04, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering l...
ReWalk Robotics Ltd. (LFWD) Q2 2024 Earnings Call Transcript
ReWalk Robotics Ltd. (NASDAQ:LFWD) Q2 2024 Earnings Conference Call August 15, 2024 8:30 AM ET Company Participants Mike Lawless - Chief Financial Officer Larry Jasinski - Chief Executive Officer Con...
Lifeward to Report Second Quarter Financial Results on August 15, 2024
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 08, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering li...
Lifeward Announces Appointment of Joseph E. Turk as Incoming Chairman of its Board of Directors
Jeff Dykan, who led Lifeward as Chairman of its Board through the past 15 years, has announced his intent to retire at the end of his current term Jeff Dykan, who led Lifeward as Chairman of its Board...
Lifeward Unveils Newest Addition to Its AlterG Anti-Gravity Product Line – Introducing AlterG NEO
The AlterG NEO combines updated user-friendly design with trusted Anti-Gravity technology for precise and consistent unweighting in physical rehabilitation and athletic training
Lifeward to Present at Sidoti Virtual Investor Conference on June 12
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 04, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering li...
ReWalk Robotics Ltd. (LFWD) Q1 2024 Earnings Call Transcript
ReWalk Robotics Ltd. (NASDAQ:LFWD) Q1 2024 Earnings Conference Call May 15, 2024 8:30 AM ET Company Participants Mike Lawless - CFO Larry Jasinski - CEO Conference Call Participants Swayampakula Rama...
Lifeward Reports First Quarter 2024 Financial Results
Q1'24 revenue of $5.3M is up 340% vs. Q1'23 and at the midpoint of Lifeward's guidance range Newly established Medicare payment for ReWalk Personal Exoskeleton favorably impacts Q1'24 results Medicare...
Lifeward to Report First Quarter Financial Results on May 15, 2024
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 07, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering lif...
Lifeward Announces the Appointment of Mike Swinford to its Board of Directors
Experienced healthcare and rehabilitation technology professional brings more than 30 years of experience in commercialization and new business development Experienced healthcare and rehabilitation te...
Medicare Revises 2024 Fee Schedule to Include Payment Rate for the ReWalk Personal Exoskeleton
Finalized Medicare reimbursement pathway for personal exoskeletons expands access for all eligible Medicare beneficiaries Finalized Medicare reimbursement pathway for personal exoskeletons expands acc...
Lifeward CEO Issues Open Letter to Shareholders on Progress to Finalize Exoskeleton Medicare Payment Rate
Collaboration with CMS on final payment rate focuses on commercial transaction values for the latest generation of ReWalk Exoskeleton
VA STAND Act introduced in the United States Senate
Bicameral legislation seeks to codify annual examinations and assessments for assistive technologies, including Personal Exoskeletons, for Veterans with Spinal Cord Injury Bicameral legislation seeks ...
Lifeward Announces Reverse Share Split
Reverse split initiated to regain compliance with Nasdaq listing requirements Financial guidance for 2024 and profitability target for 2026 on existing capital remain unchanged MARLBOROUGH, Mass. and ...
ReStore Exo-Suit Publications Demonstrate Improved Walking Outcomes Versus Conventional Stroke Therapy
Randomized clinical trial demonstrates significant improvements in walking ability for patients receiving therapy with the ReStore Exo-Suit as compared to a matched control group receiving conventiona...
Lifeward announces the Centers for Medicare & Medicaid Services (“CMS”) is deferring its final decision on the payment rate for personal exoskeletons so that more recent claims information on the current, more advanced ReWalk Personal Exoskeleton may be c
The decision was communicated through CMS' bi-annual Healthcare Common Procedure Coding System (“HCPCS”) coding memorandum released yesterday; payment amount determination for ReWalk Personal Exoskele...